USAQ · QHSLab, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Despite the extinguishment of much of the Company's debt, the Company's history of losses combined with the amount of its revenues, raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.02M | $2.69M | $2.13M | $1.41M | $1.24M | $1.41M | $124.53K | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | |
| $974.57K | $880.89K | $774.04K | $615.39K | $623.67K | $743.67K | $74.44K | — | — | — | — | — | — | — | — | — | — | |
| $2.04M | $1.81M | $1.36M | $793.61K | $619.52K | $670.75K | $50.09K | — | — | — | — | — | — | — | — | — | — | |
| — | 67.27% | 63.69% | 56.32% | 49.83% | 47.42% | 40.23% | — | — | — | — | — | — | — | — | — | — | |
| $484.01K | $484.87K | $294.48K | $214.01K | $190.12K | $90.87K | $98.29K | $100.23K | — | — | — | — | — | — | — | — | — | |
| $806.7K | $683.48K | $509.07K | $488.54K | $530.32K | $592.07K | $95.14K | — | — | — | — | — | — | — | — | — | — | |
| $597.04K | $439.14K | $276.5K | $259.11K | $387.51K | $454.01K | $131.77K | $53.87K | $27.38K | $105 | $11.97K | $38.14K | $28.93K | $60.75K | $60.5K | $67.9K | $53.67K | |
| $72.11K | $72.11K | $72.11K | $72.11K | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $72.11K | $90.73K | $146.58K | $146.58K | $127.96K | $36.06K | $0 | — | — | — | — | — | — | — | — | — | — | |
| $1.96M | $1.68M | $1.15M | $1.03M | $1.18M | $1.17M | $325.2K | $154.1K | $27.38K | — | — | — | — | — | — | — | — | |
| $34.93K | — | — | — | — | — | — | — | $27.38K | $105 | $23.25K | $722.11K | $40.48K | $69.87K | $69.62K | $77.02K | $62.79K | |
| $82.62K | $131.24K | $205.74K | -$240.16K | -$560.54K | -$502.26K | -$275.11K | -$154.1K | -$27.38K | -$105 | -$23.25K | -$722.11K | — | — | — | — | — | |
| — | 4.88% | 9.65% | -17.04% | -45.09% | -35.51% | -220.91% | — | — | — | — | — | — | — | — | — | — | |
| $154.73K | $221.97K | $352.31K | -$93.58K | -$432.58K | -$466.2K | -$275.11K | — | — | — | — | — | — | — | — | — | — | |
| $122.1K | $237.41K | $465.06K | $230.49K | $433.44K | $246.49K | $30.98K | $12.42K | $11.25K | $11.25K | $11.28K | $11.47K | $11.55K | $9120 | $9120 | $9120 | $9120 | |
| — | $457.42K | -$259.24K | -$468.36K | -$996K | -$770.18K | -$327.39K | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | $0 | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$390.73K | -$457.42K | -$259.24K | -$468.36K | -$996K | -$770.18K | -$327.39K | -$166.52K | -$38.63K | -$11.36K | -$23.25K | -$722.11K | -$40.48K | -$69.87K | -$69.62K | -$77.02K | -$62.79K | |
| — | -16.99% | -12.16% | -33.24% | -80.12% | -54.45% | -262.89% | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$69.62K | -$77.02K | — | |
| USD/shares | $0.05 | $0.04 | -$0.03 | -$0.05 | -$0.11 | -$0.10 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $0.03 | $0.02 | -$0.03 | -$0.05 | -$0.11 | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 11.3M | 10.29M | 9.42M | 9M | 7.86M | 6.2M | 5.41M | 3.59M | 3.59M | 4.19M | 3.14M | 1.09M | 1.09M | — | — | — |
| shares | — | 19.34M | 10.29M | 9.42M | 9M | 7.86M | 6.2M | 5.41M | 3.59M | 3.59M | 4.19M | 3.14M | 1.09M | 1.09M | — | — | — |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 48 similar-size Medical Devices companies (of 144 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Integrated Service Program | $1,121,134 | $643,211 | $270,022 |
| Allergy Diagnostic Kit Sales | $823,108 | $832,987 | $666,600 |
| Immunotherapy Treatment Sales | $487,762 | $409,319 | $363,184 |
| Clinical Study Revenue | $133,650 | $133,650 | — |
| Subscription Revenue | $43,731 | $54,523 | $72,200 |
| Shipping And Handling | $41,670 | $35,892 | $32,339 |
| Training and Other Revenue | $40,686 | $22,344 | $4,650 |